224 related articles for article (PubMed ID: 29145936)
1. Biosimilars: State of Clinical and Regulatory Science.
Klein AV; Wang J; Feagan BG; Omoto M
J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936
[TBL] [Abstract][Full Text] [Related]
2. The Regulation of Biosimilars in Latin America.
Garcia R; Araujo DV
Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar medicines - Review.
Dos Reis C; Teixo R; Mendes F; Cruz RS
Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
Scott BJ; Klein AV; Wang J
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Overview on Biosimilars.
Kadam V; Bagde S; Karpe M; Kadam V
Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
[TBL] [Abstract][Full Text] [Related]
7. Subsequent Entry Biologics in Canada: Current State of the Science.
Endrenyi L; Jamali F; Loebenberg R
J Pharm Pharm Sci; 2015; 18(2):177-83. PubMed ID: 26158283
[TBL] [Abstract][Full Text] [Related]
8. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
10. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
[TBL] [Abstract][Full Text] [Related]
11. Key considerations in the preclinical development of biosimilars.
Bui LA; Hurst S; Finch GL; Ingram B; Jacobs IA; Kirchhoff CF; Ng CK; Ryan AM
Drug Discov Today; 2015 May; 20 Suppl 1():3-15. PubMed ID: 25912284
[TBL] [Abstract][Full Text] [Related]
12. Approval Process: An Overview of Biosimilars in the Oncology Setting.
Sowinski-Raff L
Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
[TBL] [Abstract][Full Text] [Related]
13. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
14. [The story of biosimilars--chance or threat?].
Woroń J; Kocić I
Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars.
Malozowski S
Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
[TBL] [Abstract][Full Text] [Related]
17. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
19. The challenge of indication extrapolation for infliximab biosimilars.
Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: are they bioequivalent?
Gomollón F
Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]